Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Neoplasms 2Lung Neoplasms 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Glioblastoma 2Brain Neoplasms 2Adenocarcinoma of Lung 2Urinary Bladder Neoplasms 1Solid Tumor 1Peripheral Nervous System Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Oligodendroglioma 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1NSCLC 1Myeloproliferative Disorders 1Lymphoma, T-Cell, Cutaneous 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid 1Leukemia 1Hematologic Diseases 1Head and Neck Neoplasms 1Glioma 1Gastrointestinal Stromal Tumors 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Temozolomide 32Radiotherapy 11Bevacizumab 10Surgical Procedures, Operative 7IL13-PE38 7TIC10 compound 6Lomustine 6Carboplatin 6Radiation 5Chlorotoxin 5vorasidenib 4trametinib 4dabrafenib 4Valacyclovir 4OKN 007 4Flucytosine 4Dianhydrogalactitol 4Cyclophosphamide 4vocimagene amiretrorepvec 3abemaciclib 3Paclitaxel 3Nivolumab 3Irinotecan 3Granulocyte-Macrophage Colony-Stimulating Factor 3CLR1404 3trans-sodium crocetinate 2pembrolizumab 2olutasidenib 2marizomib 2lenvatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Glioma × BID protein, human × Clear all
NCT05561374 2024-11-29

Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma

Oblato, Inc.

Phase 1 Active not recruiting
16 enrolled
CNS

Astrocytoma, Glioblastoma, Glioma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡